Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-12-12)Premium Content

Sarepta Therapeutics Inc New (SRPT)

2015-01-29@10:03:31 ET
UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT (PMZ)

2015-01-26@18:40:44 ET
ALERT: Rosen Law Firm Reminds Sarepta Therapeutics Investors of Important February 9, 2015 Deadline in Class Action Seeking to Recover Investor Losses -- SRPT (PMZ)

2015-01-20@12:32:01 ET
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc. (BIZ)

2015-01-19@17:31:01 ET
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com (PRW)

2015-01-19@05:14:33 ET
Sarepta announces encouraging data from Phase IIb DMD study (DTM)

2015-01-19@05:13:05 ET
Sarepta initiates dosing in Phase I/II Duchenne muscular dystrophy study (DTM)

2015-01-19@01:51:04 ET
Sarepta Therapeutics Marks First Patient Dosed in European Phase I/II Study (CLM)

2015-01-15@02:29:16 ET
Sarepta Therapeutics Publishes Data on Long-Term Outcomes from Phase IIb Study (CLM)

2015-01-14@12:43:00 ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT (PRN)

2015-01-14@08:30:36 ET
Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients (BIZ)

2015-01-12@08:24:44 ET
8-K: Sarepta Therapeutics, Inc. (EDK)

2015-01-12@07:01:10 ET
Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy (BIZ)

2015-01-08@02:08:30 ET
Sarepta Therapeutics to Participate at J.P. Morgan Healthcare Conference (CLM)

2015-01-07@10:47:03 ET
Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors (BIZ)

2015-01-05@07:00:25 ET
Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare Conference (BIZ)

2015-01-02@12:39:02 ET
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 (BIZ)

2014-12-31@16:30:06 ET
Stull, Stull & Brody Announces the Investigation of Possible Breaches of Fiduciary Duties of Officers and Directors of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) (PMZ)

2014-12-29@15:55:05 ET
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT (PMZ)

2014-12-24@15:52:32 ET
SECURITIES ALERT: Rosen Law Firm Reminds Sarepta Therapeutics, Inc. Investors of Important Deadline in Class Action Seeking to Recover Investor Losses - SRPT (PMZ)

2014-12-23@08:50:00 ET
Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid (PRN)